SGLiveChat - Medtech in Australia and Singapore | SGInnovate


32 Carpenter Street
Singapore 059911

SGLiveChat - Medtech in Australia and Singapore

Presented by SGInnovate and Austrade. Partnered With: MTPConnect

In this SGLiveChat, Australian and Singaporean MedTech leaders will discuss the latest developments and their insights on emerging trends, innovations and opportunities. Join us in a conversation about the digital ecosystem in both countries and explore the new, the novel and the innovative while discussing about the opportunities the ecosystem can bring. Expand your horizons by connecting with well-known Australian Healthtech companies and fellow startups in the community.

Date : 28 September 2018, Friday
Time : 3:00pm – 6:30pm
Venue : 32 Carpenter Street, Singapore 059911


3:00 pm – 3:30 pm: Registration and Networking
3:30 pm – 3:35 pm: Opening remarks 
3:35 pm – 3:50 pm: Introduction of Australian MedTech companies
3:50 pm – 4:30 pm: SGLiveChat – Medtech in Australia and Singapore
4:30 pm – 6:30 pm: Networking and End


Ms Sue MacLeman, Chairman, MTP Connect (Australia), Delegation Lead for the Medtech to Singapore trade mission

Sue MacLeman has more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive with senior roles in corporate, medical, commercial and business development. 

Sue has also served as CEO and Board member of several ASX and NASDAQ listed companies in the sector and is currently Chair of Anatara Lifesciences Ltd, Chair of Novita Healthcare Ltd , Chair Elect and Non-Executive Director of MTPConnect (MTPII-GC Ltd), Non-Executive Director Oventus Medical Ltd, Imunexus and veski. 

Sue is also appointed to several academic and government advisory committees. Her broad commercial experience is underpinned by graduate qualifications in pharmacy and post graduate qualifications in commercial law, corporate governance, business administration and marketing.

Mr Peh Ruey Feng, CEO & Founder, Advent Access and Founding Faculty, Singapore-Stanford BioDesign

Ruey is the CEO & Founder of Advent Access Pte Ltd, a medical technology startup pioneering innovations to reduce dialysis cost and restore quality of life for kidney failure patients in Asia and across the world. Concurrently, Ruey is the Founding Faculty of the Singapore-Stanford Biodesign (SSB) office, a Medtech innovation and talent joint venture between A*STAR, EDB and Stanford University, where Ruey has been involved in pioneering since its inception and in teaching design-thinking methodology across Singapore.

Previously, Ruey was the Entrepreneur-in-Residence of A*STAR’s H&L office where he reviews and manages commercialization projects under the A*STAR-Boston CIMIT collaboration, including the spinning off of startup Hangenix Inc, in partnership with Massachusetts General Hospital, to tackle hospital-acquired infections with digital technologies.

With over 14 years’ experience in MedTech innovations, Ruey began his career in the trenches of Silicon Valley startups, first as R&D Engineer of USGI Medical Inc, then as a founding member and IP & R&D Manager of Voyage Medical Inc.

Ruey is an inventor on ~ 50 patents in renal, cardiovascular & minimally invasive surgery technologies. Ruey is the winner of the IES Prestigious Engineering Award in 2017, MIT Tech Review’s “Top 10 Innovators under 35” of Asia Pacific in 2014; and the winner of both Silicon Valley Boomers and Stanford E-Challenge business plan competitions in 2009.

Ruey is a graduate of Stanford University’s Byers Center for Biodesign as the Lucile Parkard Innovation Fellow of ‘08/09, where innovations he and his team developed led to 2 spin-offs - Orpheus Medical and Pelvalon Inc. Ruey obtained his Bachelor of Mechanical Engineering with a minor in Technopreneurship (NOC Silicon Valley) from National University of Singapore. Ruey was named Singapore’s “Top 50 Youths to Watch” by Straits Times in 2005.

Ruey serves on SPRING Singapore’s Biomedical & Health Standards Committee; and on Tan Tock Seng Hospital & National Healthcare Group’s (NHG) Center for Healthcare Innovation, Co-Learning Network.

Mr Mark Kendall, Vice-Chancellor's Entrepreneurial Professor, The Australian National University

Mark is an internationally-recognised leading innovator in producing technology solutions to global health problems; and a translator of commercial technologies focusing on delivery of drugs to skin and skin-based disease diagnostics. 

This has culminated from more than 20 years of experience researching, developing and innovating, authoring more than 200 refereed publications, and being an inventor on more than 130 patents (of which more than 70 have been granted so far). Over that time, I have worked closely with industrial partners in the technology transfer from concept to commercialisation. 

While at the University of Oxford, he contributed as an inventor of the biolistics technology, which was commercialised with PowderMed (the technology transfer company) purchased by Pfizer for $400 million in 2006. 

And in 2011, he founded Vaxxas to commercialise the Nanopatch with $15 million investment, followed by $25 million in 2015, to clinically advance the Nanopatch as a product. The Nanopatch technology has been licensed to US based pharmaceutical company Merck and Co.

In recognition of my innovation and translation, he has received numerous awards. These include: the 2016 CSL Young Florey Medal, a 2015 World Economic Forum Technology Pioneer, a 2012 Rolex Laureate for pioneering efforts to expand knowledge and improve human life, The Australian Innovation Challenge winner (2011), the Eureka Prize for Interdisciplinary Research (2011) and Younger Engineer of Britain (2004).

His work have featured in many media outlets, including: TEDGlobal, WIRED, ABC, BBC, NBC, National Geographic, New Scientist, Popular Science and Vanity Fair.
Mark is a Vice-Chancellor's Entrepreneurial Professor at ANU. At the University of Oxford (1998-2006), he was a University Research Lecturer and College Lecturer (Magdalen College). Then, he was a Professor of Biomedical Engineering at The University of Queensland (2006-2018)


Eliza Chong, Management Consultant, IQVIA

Eliza Chong is a senior level consultant, providing intelligence and solutions to the healthcare industry. She is a primary contributor for the Medtech segment in IQVIA, providing insights from her years of experience as a healthcare executive, having served in multiple commercial leadership and management roles handling major portfolios for multinationals. 

Prior to joining IQVIA, she was heading up the marketing function for one of the business units within Medtronic, orchestrating core strategic directions, resulting in the creation of profitable new markets and building up the commercial teams throughout Asia Pacific. Eliza had been involved in strategic upstream marketing and product innovations, leading to the development of tailored product lines for Asian markets. 

She holds an MBA from the National University of Singapore and an executive certificate in Strategy & Innovation from the Weatherhead School of Management - Case Western Reserve University.

Topics: MedTech / HealthTech / BioTech

You may also like the following:

  • Real Successes and Applications of Digital Health

    With levels of investments that have never been seen before (billions of dollars and counting), Digital Health is now moving faster than ever and every player in the industry needs to include it in their corporate strategies – from pharma companies to insurers, even brick and mortar hospital chains. However, the maturity level of corporates varies greatly, which dramatically impacts the success of the digitisation process in these organisations. During this fireside chat, industry veterans François Cadiou and Julien de Salaberry will share about the latest successes observed in Digital Health and how the stakeholders involved, from the corporates to the startups, manage to make it a success.


    MedTech / HealthTech / BioTech

  • Investors Night: MedTech

    With the success of our first Investors Night: Medtech, we will be organising the follow-up to the series this March.


    MedTech / HealthTech / BioTech

  • Reimbursement of Innovative Health Technologies

    A challenge for many health tech startups is pricing their products with a multitude of payers – insurance companies, governments, and hospital systems – in mind. 


    MedTech / HealthTech / BioTech

  • Corporate – Startup Collaborations in MedTech

    Today, Singapore hosts more than 200 MedTech SMEs and startups, and over 60 multinational medtech firms that undertake activities from regional headquarters and manufacturing to research and development. These companies continue to provide tangible benefits for Singapore's research, innovation and enterprise and healthcare systems, and well position Singapore to serve the larger Asian marketplace. 


    MedTech / HealthTech / BioTech, Startups

  • Rising Stars in HealthTech: Data and Artificial Intelligence

    SGInnovate, General Assembly and Galen Growth Asia are teaming up for a series of events with some of the most inspiring Southeast Asian healthtech founders and leaders. In a candid discussion, they will share their stories and insights on:


    MedTech / HealthTech / BioTech

  • Guest Writer

    Helping AI Embrace Empathy

    Artificial intelligence is already a part of our everyday lives, but for it to truly make a difference it needs to understand human emotions, says Live with AI founder Pierre Robinet.

    This article is written by Pierre Robinet, who is a senior consulting partner at Ogilvy Consulting and founder of Live With AI, an independent think tank based in Singapore.

    Topics: A.I., MedTech, Data Science / Data Analytics, Others